Overview
This Study is Designed to Characterize the Safety, Tolerability, and Anti-tumor Activity of MDX2003 in Patients With Different Types of Lymphoma
Status:
NOT_YET_RECRUITING
NOT_YET_RECRUITING
Trial end date:
2030-04-01
2030-04-01
Target enrollment:
Participant gender: